Medtronic plc (NYSE: MDT) today announced that the Resolute Onyx(TM) Drug-Eluting Stent (DES) met its primary endpoint of Target Lesion Failure (TLF) at one year for the treatment of coronary artery disease in extra-small vessels. Results from the RESOLUTE ONYX 2.0 mm Clinical Study were presented today as a Hot Line/Late-Breaking Trial Session at the 2017 EuroPCR Annual Meeting and simultaneously published in the Journal of the American College of Cardiology (JACC): Cardiovascular Intervention.

Boston Scientific’s transcatheter aortic valve implantation (TAVI) technology, the LOTUS Valve System, shows superiority to a similar platform made by a competitor in a new clinical trial.

A new study from Cincinnati’s Children’s Hospital has found that the use of a wearable cardioverter defibrillator (WCD) is safe and effective for treating ventricular arrhythmias in pediatric patients at risk from sudden cardiac death.

Apple devices just keep getting smarter. New research presented at this year’s Heart Rhythm Society (HRS) conference in Chicago showed that when paired with an artificial intelligence-based algorithm, the watch can detect atrial fibrillation (AFib). 

MARLBOROUGH, Mass., May 12, 2017 /PRNewswire/ -- Boston Scientific (NYSE: BSX) today announced positive safety and efficacy rates of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device from the EWOLUTION registry presented during a late-breaking clinical trial session at Heart Rhythm 2017, the Heart Rhythm Society's 38th Annual Scientific Sessions in Chicago. Data confirmed that the WATCHMAN device had a high implant success rate and was effective in stroke reduction for patients with non-valvular atrial fibrillation (AF), including those patients deemed unsuitable for oral anticoagulation.

The Heart Rhythm Society (HRS) recently announced the late-breaking clinical trials sessions for the upcoming Heart Rhythm scientific sessions.

Physicians in fields like cardiology have traditionally looked to clinical practice guidelines to help articulate the best evidence-based care for patients. The rapidly growing movement to value-based care is prompting clinicians—including echocardiographers—to carefully weigh a more focused and integrative approach to delivering consistent, quality medicine: care pathways.